McKesson raised its fiscal 2027 earnings guidance after pharma profit rose 19%, reflecting strength in specialty demand and oncology growth alongside disciplined spending. The update suggests improved earnings momentum and supports a more optimistic forward outlook versus prior expectations.
McKesson raised its fiscal 2027 earnings guidance after pharma profit rose 19%, reflecting strength in specialty demand and oncology growth alongside disciplined spending. The update suggests improved earnings momentum and supports a more optimistic forward outlook versus prior expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.45
Ticker Sentiment
